LN-145-S1
Phase 2Cell therapy
LN-145-S1 is one of 12 biologic programs targeting Tumor Infiltrating Lymphocytes. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Tumor Infiltrating Lymphocytes
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Paraplatin
AAvyxa
Phase 2
Alimta
SShawn Eagle
Phase 2
Amtagvi
IIovance Biotherapeutics, Inc.
Phase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Tumor Infiltrating Lymphocytes
EEssen Biotech
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LN-145-S1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- IIovance Biotherapeutics, Inc.